+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilars Market Research Report by Indication, by Manufacturing, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4807823
  • Report
  • June 2021
  • Region: Global
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Biosimilars Market Grew USD 35.62 Billion by 2026, at a CAGR of 24.10%

FEATURED COMPANIES

  • AMEGA Biotech S.A.
  • Apotex Inc.
  • Bioton S.A.
  • JHL Biotech, Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • MORE
The Global Biosimilars Market size was estimated at USD 9.75 Billion in 2020 and expected to reach USD 12.06 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 24.10% from 2020 to 2026 to reach USD 35.62 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the Biosimilars Market was examined across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
  • Based on Product, the Biosimilars Market was examined across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Recombinant Peptides is further studied across Calcitonin and Glucagon.
  • Based on Manufacturing, the Biosimilars Market was examined across Contract Manufacturing and In-House Manufacturing.
  • Based on Geography, the Biosimilars Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market, including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?
6. What is the market share of the leading vendors in the Global Biosimilars Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilars Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AMEGA Biotech S.A.
  • Apotex Inc.
  • Bioton S.A.
  • JHL Biotech, Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Product Outlook
3.4. Manufacturing Outlook
3.5. Indication Outlook
3.6. Geography Outlook
3.7. Competitor Outlook

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pressure to reduce healthcare expenditure
5.1.1.2. Growing demands of pharmaceutical drugs
5.1.1.3. Expiration of major patents during the forecast period
5.1.1.4. Supportive government initiative and awareness creating programs in the developing economies
5.1.1.5. Lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.2.2. Unawareness among patients and preference for brand
5.1.3. Opportunities
5.1.3.1. New indications and patent expiry of biologic products
5.1.3.2. Potential in emerging markets
5.1.3.3. Emergence of bio-betters drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.1.4.2. High investment required for research and development
5.2. Cumulative Impact of COVID-19
5.3. Porters Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry

6. Biosimilars Market, by Indication
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology

7. Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon

8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing

9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
9.6.1. California
9.6.2. Florida
9.6.3. Illinois
9.6.4. New York
9.6.5. Ohio
9.6.6. Pennsylvania
9.6.7. Texas

10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. China
10.3. India
10.4. Indonesia
10.5. Japan
10.6. Malaysia
10.7. Philippines
10.8. South Korea
10.9. Thailand

11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AMEGA Biotech S.A.
13.2. Amgen Inc.
13.3. Apotex Inc.
13.4. Biosidus S.A.
13.5. Bioton S.A.
13.6. Innovent Biologics, Inc.
13.7. JHL Biotech, Inc.
13.8. LG Chem, Ltd.
13.9. Merck Sharp & Dohme Corp.
13.10. Mylan N.V.
13.11. Pfizer Inc.
13.12. Sandoz International GmbH

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
14.3. Contact Details

List of Tables
TABLE 1. GLOBAL BIOSIMILARS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 31. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 32. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 33. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 34. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 35. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 36. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 37. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 38. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 39. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 40. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 41. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 42. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 43. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 44. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 45. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 46. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 47. UNITED STATES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 48. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 49. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 50. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 51. CALIFORNIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 52. CALIFORNIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 53. CALIFORNIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 54. FLORIDA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 55. FLORIDA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 56. FLORIDA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 57. ILLINOIS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 58. ILLINOIS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 59. ILLINOIS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 60. NEW YORK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 61. NEW YORK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 62. NEW YORK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 63. OHIO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 64. OHIO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 65. OHIO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 66. PENNSYLVANIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 67. PENNSYLVANIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 68. PENNSYLVANIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 69. TEXAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 70. TEXAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 71. TEXAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 72. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 73. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 74. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 75. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 76. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 77. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 78. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 79. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 80. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 81. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 82. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 83. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 84. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 85. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 86. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 87. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 88. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 89. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 90. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 91. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 92. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 93. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 94. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 95. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 96. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 97. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 98. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 99. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 104. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 105. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 106. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 107. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 108. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 109. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 110. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 111. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 112. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 113. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 114. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 115. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 116. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 117. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 118. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 119. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 120. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 121. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 122. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 123. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 124. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 125. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 126. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 127. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 128. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 129. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 130. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 131. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 132. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 133. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 134. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 135. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 136. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 137. GLOBAL BIOSIMILARS MARKET: SCORES
TABLE 138. GLOBAL BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 139. GLOBAL BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 140. GLOBAL BIOSIMILARS MARKET: RANKING
TABLE 141. GLOBAL BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 142. GLOBAL BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 143. GLOBAL BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 144. GLOBAL BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 145. GLOBAL BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 146. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING
TABLE 147. GLOBAL BIOSIMILARS MARKET: CONTACT DETAILS
Note: Product cover images may vary from those shown
  • AMEGA Biotech S.A.
  • Amgen Inc.
  • Apotex Inc.
  • Biosidus S.A.
  • Bioton S.A.
  • Innovent Biologics, Inc.
  • JHL Biotech, Inc.
  • LG Chem, Ltd.
  • Merck Sharp & Dohme Corp.
  • Mylan N.V.
  • Pfizer Inc.
  • Sandoz International GmbH
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll